|
Frequency (percentage) and binary logistic regression estimates of crude and multivariable O.R. and associated 95% confidence intervals (95%CI). |
|||||
| Exposure |
Symptoms |
||||
|
|
|||||
| Cyanobacterial cell surface area1 |
None |
Present |
Crude models2 |
Multivariable3 |
|
| n (%) |
n (%) |
O.R. (95%CI) |
O.R. (95%CI) |
||
| Any symptom |
|||||
| Low |
569 (70) |
241 (30) |
1 |
1 |
|
| Intermediate |
134 (74) |
46 (26) |
0.8 (0.6–1.2) |
0.8 (0.6–1.3) |
|
| High |
99 (67) |
48 (33) |
1.6 (1.0–2.7) |
1.7 (1.0–2.9) |
|
| Ear symptoms |
|||||
| Low |
895 (96) |
33 (4) |
1 |
1 |
|
| Intermediate |
199 (98) |
4 (2) |
0.6 (0.2–1.5) |
0.5 (0.2–1.5) |
|
| High |
159 (96) |
7 (4) |
1.9 (0.6–6.5) |
2.0 (0.6–7.1) |
|
| Eye symptoms |
|||||
| Low |
872 (94) |
59 (6) |
1 |
1 |
|
| Intermediate |
196 (95) |
10 (5) |
0.8 (0.4–1.8) |
0.8 (0.4–1.9) |
|
| High |
154 (95) |
9 (6) |
0.6 (0.2–1.6) |
0.6 (0.3–1.7) |
|
| G-I symptoms |
|||||
| Low |
871 (94) |
57 (6) |
1 |
1 |
|
| Intermediate |
199 (95) |
10 (5) |
0.9 (0.4–1.7) |
0.9 (0.4–1.8) |
|
| High |
158 (95) |
8 (5) |
0.9 (0.3–2.2) |
0.9 (0.4–2.2) |
|
| Respiratory symptoms |
|||||
| Low |
691 (86) |
116 (14) |
1 |
1 |
|
| Intermediate |
169 (88) |
24 (12) |
1.0 (0.6–1.6) |
0.9 (0.6–1.6) |
|
| High |
122 (82) |
27 (18) |
2.0 (1.1–3.7) |
2.1 (1.1–4.0) |
|
| Cutaneous symptoms |
|||||
| Low |
875 (95) |
43 (5) |
1 |
1 |
|
| Intermediate |
197 (96) |
8 (4) |
0.7 (0.3–1.7) |
0.7 (0.3–1.8) |
|
| High |
159 (96) |
7 (4) |
1.9 (0.9–4.3) |
1.9 (0.9–4.4) |
|
| Fever |
|||||
| Low |
938 (99) |
10 (1) |
1 |
1 |
|
| Intermediate |
208 (99) |
3 (1) |
1.5 (0.4–5.6) |
1.8 (0.5–6.7) |
|
| High |
165 (99) |
2 (1) |
2.0 (0.5–8.7) |
1.8 (0.4–8.1) |
|
| Any symptom – after exclusion of subjects with recent (5 days prior to recruitment) exposure |
|||||
| Low |
436 (67) |
200 (31) |
1 |
1 |
|
| Intermediate |
74 (69) |
33 (31) |
0.9 (0.6–1.5) |
0.9 (0.6–1.5) |
|
| High |
71 (69) |
32 (31) |
1.5 (0.8–2.9) |
1.6 (0.8–3.2) |
|
|
1: Low = <2.4 mm2/mL; intermediate = 2.4 - 12.0 mm2/mL; high = >12.0 mm2/mL 2: Adjusted for geographic region (QLD, NSW, Florida) as a design variable and clustered by household 3: Adjusted for geographic region (QLD, NSW, Florida), age-group, sex, smoking and reported prior history of asthma, hay fever or eczema, and clustered by household | |||||
Stewart et al. BMC Public Health 2006 6:93 doi:10.1186/1471-2458-6-93 |
|||||